journal article·2025-04Open access

Macrophage and osteosarcoma cell crosstalk is dependent on oxygen tension and 3D culture

Katherine H. Griffin, Isabel S. Sagheb, Thomas P. Coonan, Fernando A. Fierro, R. Lor Randall, J. Kent Leach

Abstract

Osteosarcoma (OS), the most common form of primary bone cancer in young adults, has had no improvements in clinical outcomes in 50 years. This highlights a critical need to advance mechanistic understanding of OS to further therapeutic discovery, which will only be possible with accurate models of the disease. Compared to traditional monolayer studies and preclinical models, in vitro models that better replicate the three-dimensional (3D) bone marrow microenvironment will facilitate methodical investigations of the events and factors that drive OS progression. Herein, we use fibrin-alginate interpenetrating network (FA IPN) hydrogels to model the hematological bone marrow environment. We interrogated the effects of oxygen tension, 3D culture, and macrophage phenotype on OS behavior and specifically examine the immunomodulatory crosstalk between OS and macrophages. We observe that OS is more sensitive to oxygen tension when cultured in 3D. Specifically, both highly and less metastatic OS exhibit decreased changes in DNA content over time in 3D, but then demonstrate diverging behaviors in heterotypic culture with macrophages. OS response to macrophages differs as a function of metastatic potential, where highly metastatic OS shows increased immunosuppression that varies with oxygen tension but relies on direct coculture conditions. To our knowledge, this is among the first work to report the effects of 3D culture on the interplay between OS and macrophages in a coculture microenvironment. Together, these data introduce FA IPNs as a promising platform for cancer research and emphasize the importance of novel models for the mechanistic study of OS.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · 3D Printing in Biomedical Research · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (78)

Show source-provided references
1. Osteosarcoma: a review of diagnosis, management, and treatment strategies
2. Osteosarcoma
3. Self-perception and quality of life in adolescents during treatment for a primary malignant bone tumour10.1016/j.ejon.2014.01.005 ↗
4. Quality of life in young patients after bone tumor surgery around the knee joint and comparison with healthy controls10.1002/pbc.22439 ↗
5. Tissue engineered platforms for studying primary and metastatic neoplasm behavior in bone10.1016/j.jbiomech.2020.110189 ↗
6. In vitro studies of osteosarcoma: a researcher’s perspective of quantity and quality10.1016/j.jbo.2017.04.004 ↗
8. Relevance of 3d culture systems to study osteosarcoma environment10.1186/s13046-017-0663-5 ↗
9. Scaffold-based 3d cellular models mimicking the heterogeneity of osteosarcoma stem cell niche10.1038/s41598-020-79448-y ↗
10. Micrometastatic drug screening platform shows heterogeneous response to map chemotherapy in osteosarcoma cell lines10.1007/s11999.0000000000000059 ↗
11. A spheroid model of early and late-stage osteosarcoma mimicking the divergent relationship between tumor elimination and bone regeneration10.1002/adhm.202101296 ↗
12. A 3d osteosarcoma model with bone-mimicking cues reveals a critical role of bone mineral and informs drug discovery10.1002/adhm.202200768 ↗
13. Selective effects of hydroxyapatite nanoparticles on osteosarcoma cells and osteoblasts10.1007/s10856-012-4703-6 ↗
14. Osteomimetic matrix components alter cell migration and drug response in a 3d tumour-engineered osteosarcoma model10.1016/j.actbio.2019.07.011 ↗
15. A 3d bioprinted nanoengineered hydrogel with photoactivated drug delivery for tumor apoptosis and simultaneous bone regeneration via macrophage immunomodulation10.1002/mabi.202300096 ↗
16. A 3d-printed biomaterials-based platform to advance established therapy avenues against primary bone cancers10.1016/j.actbio.2020.10.006 ↗
17. Time-sequential and multi-functional 3d printed mgo(2)/plga scaffold developed as a novel biodegradable and bioactive bone substitute for challenging postsurgical osteosarcoma treatment
18. A 3d-printed scaffold-based osteosarcoma model allows to investigate tumor phenotypes and pathogenesis in an in vitro bone-mimicking niche
19. Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening10.1073/pnas.2302101120 ↗
20. Engineering fibrin hydrogels to promote the wound healing potential of mesenchymal stem cell spheroids10.1016/j.actbio.2017.10.007 ↗
21. Fibrin: a versatile scaffold for tissue engineering applications10.1089/ten.teb.2007.0435 ↗
22. Bio-instructive materials for musculoskeletal regeneration10.1016/j.actbio.2019.07.014 ↗
23. Tunable fibrin-alginate interpenetrating network hydrogels to support cell spreading and network formation10.1016/j.actbio.2020.03.014 ↗
24. Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy10.3390/ijms21155207 ↗
25. Macrophages in osteosarcoma immune microenvironment: implications for immunotherapy10.3389/fonc.2020.586580 ↗
26. The role of tumour-associated macrophages in bone metastasis10.1016/j.jbo.2016.03.004 ↗
27. Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma10.1111/vco.12444 ↗
28. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma10.18632/oncotarget.13055 ↗
29. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents10.1158/1078-0432.CCR-10-2047 ↗
30. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential10.1023/A:1006767007547 ↗
31. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells10.18632/oncotarget.5177 ↗
32. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma10.1111/j.1432-0436.1988.tb00090.x ↗
33. Extended culture of macrophages from different sources and maturation results in a common m2 phenotype10.1002/jbm.a.35415 ↗
34. Macrophage polarization impacts tunneling nanotube formation and intercellular organelle trafficking10.1038/s41598-019-50971-x ↗
35. Sulfated alginate hydrogels prolong the therapeutic potential of msc spheroids by sequestering the secretome
36. Multisized photoannealable microgels regulate cell spreading, aggregation, and macrophage phenotype through microporous void space10.1002/adhm.202202239 ↗
37. Extracellular vesicles from highly metastatic osteosarcoma cells induce pro-tumorigenic macrophage phenotypes10.1002/adbi.202300577 ↗
38. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution10.1016/j.biomaterials.2004.06.044 ↗
39. Cell migration and bone formation from mesenchymal stem cell spheroids in alginate hydrogels are regulated by adhesive ligand density10.1021/acs.biomac.7b01366 ↗
40. High mannose n-glycans promote migration of bone-marrow-derived mesenchymal stromal cells10.3390/ijms21197194 ↗
41. Preclinical evaluation of mesenchymal stem cells overexpressing vegf to treat critical limb ischemia10.1038/mtm.2016.53 ↗
42. Mechanics of intact bone marrow10.1016/j.jmbbm.2015.06.023 ↗
43. New advances in the study of bone tumors: a lesson from the 3d environment
44. Recent and ongoing research into metastatic osteosarcoma treatments10.3390/ijms23073817 ↗
45. Osteosarcoma treatment – where do we stand?10.1016/j.ctrv.2013.11.006 ↗
46. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials10.1186/s40425-017-0301-y ↗
47. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (sarc028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial10.1016/S1470-2045(17)30624-1 ↗
48. Bone sarcomas in the immunotherapy era10.1111/bph.14999 ↗
49. Pd-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse10.1186/s13045-018-0560-1 ↗
50. Establishment of humanised xenograft models as in vivo study for lung metastasis of osteosarcoma10.1093/immadv/ltae002 ↗
51. A humanised rat model of osteosarcoma reveals ultrastructural differences between bone and mineralised tumour tissue10.1016/j.bone.2021.116018 ↗
52. Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma10.1016/j.biomaterials.2018.04.030 ↗
53. Generating murine osteoclasts from bone marrow
54. Concepts of extracellular matrix remodelling in tumour progression and metastasis10.1038/s41467-020-18794-x ↗
55. Mechanical property of hydrogels and the presence of adipose stem cells in tumor atroma affect spheroid formation in the 3d osteosarcoma model10.1021/acsami.8b22724 ↗
56. Three-dimensional osteosarcoma models for advancing drug discovery and development10.1002/adtp.201800108 ↗
57. Inhibition of macrophage polarization prohibits growth of human osteosarcoma10.1007/s13277-014-2005-y ↗
58. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the cox-2/stat3 axis10.1016/j.canlet.2018.10.011 ↗
59. Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma
60. Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks10.1158/1078-0432.CCR-22-1471 ↗
61. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma10.1111/cas.14398 ↗
62. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications10.1007/s13402-021-00598-w ↗
63. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the children’s oncology group10.1002/cncr.24566 ↗
64. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments10.1002/pbc.24686 ↗
65. Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - observational prospective single institution analysis10.1016/j.jbo.2021.100362 ↗
66. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases
67. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages
68. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes10.1016/S0022-3565(25)38958-5 ↗
69. Tumor-associated macrophages induce inflammation and drug resistance in a mechanically tunable engineered model of osteosarcoma10.1016/j.biomaterials.2023.122076 ↗
70. Enhancing osteosarcoma therapy through aluminium hydroxide nanosheets-enabled macrophage modulation10.1016/j.ijpharm.2023.123640 ↗
71. Tumor-derived exosomes induced m2 macrophage polarization and promoted the metastasis of osteosarcoma cells through tim-310.1016/j.arcmed.2020.10.018 ↗
72. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an m2 tumor-promoting phenotype and inhibits tumoricidal functions10.1080/2162402X.2020.1747677 ↗
73. Pitx1 suppresses osteosarcoma metastasis through exosomal linc00662-mediated m2 macrophage polarization10.1007/s10585-022-10192-5 ↗
74. Hypoxia inducible factor pathway and physiological adaptation: a cell survival pathway?10.1155/2015/584758 ↗
75. A humanized bone microenvironment uncovers hif2 alpha as a latent marker for osteosarcoma10.1016/j.actbio.2019.02.051 ↗
76. Chapter 9 - the respiratory system: anatomy, physiology, and adaptations to exercise and training
77. Collagen i regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent of s100a410.1111/j.1742-4658.2009.07223.x ↗
78. Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma10.1038/s41413-022-00237-6 ↗